Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Special protocol assessment process for the dipeptidyl peptidase inhibitor would have delayed start of Phase III non-small cell lung cancer trials, exec says.
You may also be interested in...
Point Therapeutics’ Oncologic Talabostat On Clinical Hold
Poor interim trial results, cash crunch may force Boston company to reduce operations.
Point Therapeutics’ Oncologic Talabostat On Clinical Hold
Poor interim trial results, cash crunch may force Boston company to reduce operations.
FDA Workshop To Discuss Brain Tumor Trial Endpoints
The Jan. 20 public meeting is next in a series of meetings on oncology endpoints.